Bleakley Financial Group LLC Has $259,000 Stock Position in Humana Inc. (NYSE:HUM)

Bleakley Financial Group LLC decreased its position in Humana Inc. (NYSE:HUM) by 44.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,020 shares of the insurance provider’s stock after selling 821 shares during the period. Bleakley Financial Group LLC’s holdings in Humana were worth $259,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FNY Investment Advisers LLC grew its holdings in shares of Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after buying an additional 26,856 shares during the period. Retirement Systems of Alabama grew its holdings in shares of Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after buying an additional 192,801 shares during the period. PDT Partners LLC grew its holdings in shares of Humana by 190.0% in the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after buying an additional 2,660 shares during the period. Secure Asset Management LLC acquired a new position in shares of Humana in the 4th quarter valued at $244,000. Finally, Ontario Teachers Pension Plan Board grew its holdings in shares of Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after buying an additional 71,910 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

HUM has been the subject of several research analyst reports. Morgan Stanley boosted their price target on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Barclays upped their target price on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. Wells Fargo & Company reduced their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Truist Financial upped their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Finally, Piper Sandler upped their target price on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $297.68.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.32% of the company’s stock.

Humana Stock Performance

Shares of NYSE:HUM opened at $256.69 on Wednesday. The company’s 50 day moving average price is $273.69 and its two-hundred day moving average price is $296.67. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The firm has a market cap of $30.91 billion, a PE ratio of 22.74, a PEG ratio of 2.11 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities research analysts predict that Humana Inc. will post 16.11 earnings per share for the current year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.